STERIS Q1 revenue rises 7% to $1.5 billion; plans $55-70 million restructuring
STERIS reported fiscal 2027 first-quarter revenue up 7% to $1.5 billion and diluted EPS of $2.04, up from $1.79, with adjusted EPS of $2.59 versus $2.34. It reiterated its full-year revenue and adjusted EPS guidance, but raised its capital expenditure outlook and lowered its free cash flow outlook, and it announced a consolidation of U.S. chemistries manufacturing that includes closing facilities in St. Louis, Missouri, and Plymouth, Minnesota.
Key points
- Q1 fiscal 2027 revenue rose 7% to $1.5 billion; Healthcare revenue grew 8% to $1.05 billion.
- Free cash flow fell to $279.6 million from $326.5 million; operating cash flow was $367.1 million versus $420.0 million.
- Expected pre-tax restructuring charges of $55 million to $70 million, with completion anticipated during fiscal 2030.
- Full-year free cash flow outlook cut to about $800 million from $850 million, while capital expenditures are now expected at about $450 million versus $375 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.